Integrated Center for Genes, Environment, and Health, National Jewish Health, Denver, Colo.
Department of Medicine, University of California-San Francisco, San Francisco, Calif.
J Allergy Clin Immunol. 2014 Mar;133(3):670-8.e12. doi: 10.1016/j.jaci.2013.11.025. Epub 2014 Feb 2.
Bronchial airway expression profiling has identified inflammatory subphenotypes of asthma, but the invasiveness of this technique has limited its application to childhood asthma.
We sought to determine whether the nasal transcriptome can proxy expression changes in the lung airway transcriptome in asthmatic patients. We also sought to determine whether the nasal transcriptome can distinguish subphenotypes of asthma.
Whole-transcriptome RNA sequencing was performed on nasal airway brushings from 10 control subjects and 10 asthmatic subjects, which were compared with established bronchial and small-airway transcriptomes. Targeted RNA sequencing nasal expression analysis was used to profile 105 genes in 50 asthmatic subjects and 50 control subjects for differential expression and clustering analyses.
We found 90.2% overlap in expressed genes and strong correlation in gene expression (ρ = .87) between the nasal and bronchial transcriptomes. Previously observed asthmatic bronchial differential expression was strongly correlated with asthmatic nasal differential expression (ρ = 0.77, P = 5.6 × 10(-9)). Clustering analysis identified TH2-high and TH2-low subjects differentiated by expression of 70 genes, including IL13, IL5, periostin (POSTN), calcium-activated chloride channel regulator 1 (CLCA1), and serpin peptidase inhibitor, clade B (SERPINB2). TH2-high subjects were more likely to have atopy (odds ratio, 10.3; P = 3.5 × 10(-6)), atopic asthma (odds ratio, 32.6; P = 6.9 × 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 × 10(-6)), and rhinitis (odds ratio, 8.3; P = 4.1 × 10(-6)) compared with TH2-low subjects. Nasal IL13 expression levels were 3.9-fold higher in asthmatic participants who experienced an asthma exacerbation in the past year (P = .01). Several differentially expressed nasal genes were specific to asthma and independent of atopic status.
Nasal airway gene expression profiles largely recapitulate expression profiles in the lung airways. Nasal expression profiling can be used to identify subjects with IL13-driven asthma and a TH2-skewed systemic immune response.
支气管气道表达谱已鉴定出哮喘的炎症亚表型,但该技术的侵入性限制了其在儿童哮喘中的应用。
我们旨在确定鼻转录组是否可以代表哮喘患者肺气道转录组的表达变化。我们还试图确定鼻转录组是否可以区分哮喘的亚表型。
对 10 名对照受试者和 10 名哮喘受试者的鼻气道刷取物进行全转录组 RNA 测序,并与已建立的支气管和小气道转录组进行比较。使用靶向 RNA 测序鼻表达分析对 50 名哮喘受试者和 50 名对照受试者的 105 个基因进行差异表达和聚类分析。
我们发现鼻和支气管转录组之间表达基因的 90.2%重叠,基因表达具有很强的相关性(ρ=0.87)。先前观察到的哮喘支气管差异表达与哮喘鼻差异表达强烈相关(ρ=0.77,P=5.6×10(-9))。聚类分析确定了 TH2-高和 TH2-低两组,通过 70 个基因的表达来区分,包括 IL13、IL5、periostin(POSTN)、钙激活氯离子通道调节剂 1(CLCA1)和丝氨酸蛋白酶抑制剂,B 族(SERPINB2)。TH2-高组更有可能患有特应性(优势比,10.3;P=3.5×10(-6))、特应性哮喘(优势比,32.6;P=6.9×10(-7))、高血嗜酸性粒细胞计数(优势比,9.1;P=2.6×10(-6))和鼻炎(优势比,8.3;P=4.1×10(-6)),与 TH2-低组相比。在过去一年中经历哮喘加重的哮喘参与者中,鼻 IL13 表达水平高出 3.9 倍(P=0.01)。一些差异表达的鼻基因是特发性哮喘特有的,与特应性状态无关。
鼻气道基因表达谱在很大程度上再现了肺气道的表达谱。鼻表达谱分析可用于识别具有 IL13 驱动的哮喘和 TH2 偏向的全身免疫反应的患者。